King Luther Capital Management Corp Boosts Holdings in Cellebrite DI Ltd. $CLBT

King Luther Capital Management Corp lifted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 17.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 354,184 shares of the company’s stock after purchasing an additional 52,945 shares during the period. King Luther Capital Management Corp’s holdings in Cellebrite DI were worth $6,386,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Cellebrite DI by 16.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after acquiring an additional 24,881 shares during the period. Geode Capital Management LLC lifted its position in Cellebrite DI by 16.2% during the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after acquiring an additional 43,898 shares during the period. Invesco Ltd. lifted its position in Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after acquiring an additional 209,473 shares during the period. First Trust Advisors LP purchased a new position in Cellebrite DI during the 2nd quarter valued at about $341,000. Finally, Marshall Wace LLP purchased a new position in Cellebrite DI during the 2nd quarter valued at about $4,472,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on CLBT. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. DA Davidson began coverage on shares of Cellebrite DI in a research report on Wednesday. They set a “buy” rating and a $20.00 price target for the company. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $12.70 on Thursday. The firm has a market cap of $3.17 billion, a P/E ratio of 45.36, a P/E/G ratio of 1.54 and a beta of 1.15. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98. The firm has a 50-day simple moving average of $13.29 and a two-hundred day simple moving average of $15.31.

Insiders Place Their Bets

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 13,269 shares of company stock worth $169,592. 5.70% of the stock is currently owned by company insiders.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.